Latest revenue
$251.0K
as of 2024-09-30
Latest net income
$-17.5M
as of 2024-09-30
Net margin
-6961.0%
as of 2024-09-30
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Biological Products, (No Diagnostic Substances) (165 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ARTV is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $168.9M
- Enterprise value
- $148.0M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.92×
- Dividend yield
- 0.0%
- 52-wk high
- $14.53
- 52-wk low
- $1.47
- Beta
- —
- Shares out
- 24.7M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Overview We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Our product candidates are derived from donor cells (allogeneic) rather than a patient’s own cells (autologous) and are pre-manufactured and stored frozen and ready to ship to a patient’s treatment location, making them what we believe to be “off-the-shelf.” Our lead product candidate, AlloNK (also known as AB-101), is an allogeneic, non-genetically modified, cryopreserved NK cell therapy designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of monoclonal…
AI summary unavailable — showing raw filing excerpt
Generated from ARTV's filing dated 2026-03-10
Key risks
Item 1A. Risk Factors You should carefully consider the risks and uncertainties described below, as well as the other information in this Annual Report on Form 10-K and in our other public filings, including in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in our financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K and in our other public filings, which could materially affect our business, financial condition or future results. The risks described below are not the only risks that we face. The occurrence of any of the following risks, or of additional risks and uncertainties not…
AI summary unavailable — showing raw filing excerpt
Generated from ARTV's filing dated 2026-03-10
Profitability
Operating margin
-26805.6%
29171.1%Net margin
-26045.0%
30272.6%Return on equity
-44.9%
28.3%Return on assets
-64.0%
105.3%Leverage
Debt / equity
-0.30×
342.8%Long-term debt / equity
0.00×
Debt / assets
-42.5%
488.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-23.5M | -15.8% | — |
Q4 2025 2025-12-31 | — | — | $-20.8M | -29.1% | — |
Q3 2025 2025-09-30 | — | — | $-21.5M | -23.2% | — |
Q2 2025 2025-06-30 | — | — | $-21.3M | -19.1% | — |
Q1 2025 2025-03-31 | — | — | $-20.3M | -45.5% | — |
Q4 2024 2024-12-31 | — | — | $-16.1M | — | — |
Q3 2024 2024-09-30 | $251.0K | -99.1% | $-17.5M | -254.9% | -6961.0% |
Q2 2024 2024-06-30 | $251.0K | -92.8% | $-17.8M | -58.1% | -7108.8% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on ARTV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$100.0M
Insider selling
$741.0K
Net activity
+$99.3M
Distinct insiders
6
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ARTV
Institutional value
$7.1M
Total shares held
1.1M
Distinct holders
15
-19 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | FRANKLIN RESOURCES INC | 520.3K | $3.4M | +0 (+0.0%) | No change |
| 2 | BlackRock, Inc. | 213.4K | $1.4M | +850 (+0.4%) | Added |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 207.7K | $1.3M | — | New |
| 4 | JANE STREET GROUP, LLC | 39.5K | $254.4K | -1.2K (-2.9%) | Trimmed |
| 5 | VANGUARD FIDUCIARY TRUST CO | 32.8K | $211.3K | — | New |
| 6 | Simplify Asset Management Inc. | 23.2K | $149.6K | — | New |
| 7 | Sanctuary Advisors, LLC | 21.6K | $139.0K | — | New |
| 8 | BAILARD, INC. | 20.7K | $133.3K | — | New |
| 9 | DIMENSIONAL FUND ADVISORS LP | 20.4K | $131.2K | — | New |
| 10 | Russell Investments Group, Ltd. | 5.5K | $35.4K | +0 (+0.0%) | No change |
| 11 | UBS Group AG | 1.5K | $9.8K | -35.3K (-95.9%) | Trimmed |
| 12 | WELLS FARGO & COMPANY/MN | 1.5K | $9.7K | +0 (+0.0%) | No change |
| 13 | MARK SHEPTOFF FINANCIAL PLANNING, LLC | 400 | $4.2K | +0 (+0.0%) | No change |
| 14 | BNP PARIBAS FINANCIAL MARKETS | 542 | $3.5K | +0 (+0.0%) | No change |
| 15 | JPMORGAN CHASE & CO | 223 | $1.2K | +36 (+19.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ARTV's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.